Future PharmaTech
Update:2026/03/24
Industries
Main Industry
Biotechnology
Founded Year
2021
Unified Business No.
90511221
Status
Active
Number of Employees
0
Total Paid-in
Capital
47,899,769 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Future PharmaTech Co., Ltd. founded in 2021, focuses on neurological and vascular networks, advancing AI-powered drug discovery and nanomedicine to develop targeted therapies for dementia and erectile dysfunction (ED).
Our mission is "restoring patients' quality of life" through treatments that combine efficacy with comfort. Our Future-AI platform integrates drug repurposing and mechanism simulation to penetrate the blood-brain barrier (BBB) and improve outcomes while minimizing side effects.
we collaborate globally to shorten drug development to within five years, delivering breakthrough therapies that benefit patients worldwide.
Our mission is "restoring patients' quality of life" through treatments that combine efficacy with comfort. Our Future-AI platform integrates drug repurposing and mechanism simulation to penetrate the blood-brain barrier (BBB) and improve outcomes while minimizing side effects.
we collaborate globally to shorten drug development to within five years, delivering breakthrough therapies that benefit patients worldwide.